These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
365 related items for PubMed ID: 24905724
1. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gadducci A, Lanfredini N, Tana R. Gynecol Endocrinol; 2014 Sep; 30(9):612-7. PubMed ID: 24905724 [Abstract] [Full Text] [Related]
2. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Xiao W, Awadallah A, Xin W. Int J Clin Exp Pathol; 2012 Sep; 5(7):642-50. PubMed ID: 22977660 [Abstract] [Full Text] [Related]
3. ARID1A mutations in endometriosis-associated ovarian carcinomas. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. N Engl J Med; 2010 Oct 14; 363(16):1532-43. PubMed ID: 20942669 [Abstract] [Full Text] [Related]
4. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes-Masson AM. Int J Gynaecol Obstet; 2015 Jul 14; 130(1):27-30. PubMed ID: 25912412 [Abstract] [Full Text] [Related]
5. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM. Int J Gynecol Cancer; 2012 Oct 14; 22(8):1310-5. PubMed ID: 22976498 [Abstract] [Full Text] [Related]
6. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Mod Pathol; 2012 Apr 14; 25(4):615-24. PubMed ID: 22157930 [Abstract] [Full Text] [Related]
7. Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Worley MJ, Liu S, Hua Y, Kwok JS, Samuel A, Hou L, Shoni M, Lu S, Sandberg EM, Keryan A, Wu D, Ng SK, Kuo WP, Parra-Herran CE, Tsui SK, Welch W, Crum C, Berkowitz RS, Ng SW. Eur J Cancer; 2015 Sep 14; 51(13):1831-42. PubMed ID: 26059197 [Abstract] [Full Text] [Related]
8. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Cancer; 2002 Jun 01; 94(11):2935-40. PubMed ID: 12115382 [Abstract] [Full Text] [Related]
10. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Matsumoto T, Yamazaki M, Takahashi H, Kajita S, Suzuki E, Tsuruta T, Saegusa M. Am J Clin Pathol; 2015 Sep 01; 144(3):452-63. PubMed ID: 26276776 [Abstract] [Full Text] [Related]
11. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Munksgaard PS, Blaakaer J. Gynecol Oncol; 2012 Jan 01; 124(1):164-9. PubMed ID: 22032835 [Abstract] [Full Text] [Related]
12. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Suda K, Cruz Diaz LA, Yoshihara K, Nakaoka H, Yachida N, Motoyama T, Inoue I, Enomoto T. Cancer Sci; 2020 Aug 01; 111(8):3000-3009. PubMed ID: 32473611 [Abstract] [Full Text] [Related]
13. Endometrioid adenocarcinoma of the ovary and endometriosis. Valenzuela P, Ramos P, Redondo S, Cabrera Y, Alvarez I, Ruiz A. Eur J Obstet Gynecol Reprod Biol; 2007 Sep 01; 134(1):83-6. PubMed ID: 16844279 [Abstract] [Full Text] [Related]
14. Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2. Lai CR, Hsu CY, Chen YJ, Yen MS, Chao KC, Li AF. J Chin Med Assoc; 2013 Nov 01; 76(11):629-34. PubMed ID: 23962610 [Abstract] [Full Text] [Related]
15. Alterations in β-catenin, microsatellite instability, and HNF-1β levels are independently associated with ovarian endometriosis-associated tumorigenesis. Tomohiro M, Matsumoto T, Miura R, Oguri Y, Yokoi A, Tochimoto M, Saegusa M. Hum Pathol; 2019 Jul 01; 89():10-23. PubMed ID: 31022415 [Abstract] [Full Text] [Related]
16. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer. Er TK, Su YF, Wu CC, Chen CC, Wang J, Hsieh TH, Herreros-Villanueva M, Chen WT, Chen YT, Liu TC, Chen HS, Tsai EM. J Mol Med (Berl); 2016 Jul 01; 94(7):835-47. PubMed ID: 26920370 [Abstract] [Full Text] [Related]
17. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Best Pract Res Clin Obstet Gynaecol; 2004 Apr 01; 18(2):349-71. PubMed ID: 15157647 [Abstract] [Full Text] [Related]
20. Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes. Sekizawa A, Amemiya S, Otsuka J, Saito H, Farina A, Okai T, Tachikawa T. Med Electron Microsc; 2004 Jun 01; 37(2):97-100. PubMed ID: 15221651 [Abstract] [Full Text] [Related] Page: [Next] [New Search]